EMG
NVCR icon

Ellington Management Group’s NovoCure NVCR Stock Holding History

Ellington Management Group’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-4,800
Closed -$359K – 688
2019
Q3 		$359K Sell
4,800
-3,700
-44% -$296K 0.06% 314
2019
Q2 		$537K Buy
+8,500
New +$431K 0.09% 222
2018
Q4 		– Sell
-8,100
Closed -$424K – 539
2018
Q3 		$424K Buy
+8,100
New +$322K 0.11% 235
2017
Q3 		– Sell
-20,700
Closed -$358K – 788
2017
Q2 		$358K Sell
20,700
-5,700
-22% -$73.6K 0.05% 345
2017
Q1 		$214K Buy
+26,400
New +$191K 0.01% 566

Other funds holding NVCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
DCP
Darsana Capital Partners New York $4.7B AUM 50.56% 1-Year Est. Return

Ellington Management Group's NVCR Position: Q4 2019 in Review

Ellington Management Group sold out of NovoCure (NVCR) in Q4 2019, closing a stake of 4,800 shares — an estimated $359K sold.

Ellington Management Group first reported a position in NVCR in Q1 2017 and held it in 5 quarters. The position peaked at $537K in Q2 2019. 262 funds tracked by Wall St. Rank hold NVCR as of Q4 2019.

  • Ellington Management Group reported no remaining NovoCure position as of Q4 2019 after selling out during the quarter.
  • Ellington Management Group sold 4,800 NovoCure shares in Q4 2019, an estimated $359K.
  • Ellington Management Group first reported a position in NovoCure in Q1 2017 and held it in 5 quarters.
  • Ellington Management Group's NovoCure position peaked at $537K in Q2 2019.
  • 262 funds tracked by Wall St. Rank held NovoCure as of Q4 2019.

Based on Ellington Management Group's 13F filing for Q4 2019, filed 14 Feb 2020.